Answers are grounded in this paper and cite their sources.
Shows how cell-cycle-specific lesions affect radiosensitization in cancer cells, suggesting improved treatment scheduling.
DNA double‐strand breaks (DSBs) generated from collisions of DNA replication forks with cisplatin‐induced interstrand crosslinks underpin cisplatin cytotoxicity. Yet, the impact of cell‐cycle‐dependent cisplatin–DNA adduct (CDA) formation on cell cycle progression and interactions with DNA replication remain incompletely characterized. Also, although cisplatin enhances tumor response to ionizing radiation (IR), the underpinning radiosensitizing mechanisms remain unresolved. Here, we close this void and analyze CDAs (GpG crosslinks) and DSB (γH2AX foci) induction and repair in a strictly cell‐cycle‐dependent manner. We report for the first time that CDAs form in a dose‐ and time‐dependent manner in all cell cycle phases, whereas DSBs emerge only in S‐phase. Repair of IR‐induced DSBs remains largely unaffected by CDAs in G 1 , S, and G 2 phases, but is inhibited when S‐phase‐treated cells progressed to G 2 . Radiosensitization occurs after prolonged cisplatin exposure, likely owing to G 2 ‐phase accumulation and lesion evolution from S‐phase, thus impairing repair of IR‐induced DSBs. Cisplatin fails to radiosensitize quiescent (G 0 ) cells. In summary, CDA formation is similar across the cell cycle, but DSBs form only in S‐phase. Whereas CDAs fail to interfere with repair of IR‐induced DSBs, progression‐dependent repair disruptions cause radiosensitization. Elucidation of the underpinning mechanisms may help to design improved cisplatin–radiation schedules for more efficacious therapies.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: